Accuray will showcase its CyberKnife® and TomoTherapy® Systems at CHINA-HOSPEQ 2013
SUNNYVALE, Calif., Aug. 16, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today its participation in the 22nd China International Medical Instruments and Equipment Exhibition and Seminar (CHINA-HOSPEQ), taking place from Friday, August 16 to Sunday, August 18, 2013.
For the first time, China's hospital procurement officials will be able to see firsthand Accuray's CyberKnife and TomoTherapy Systems at CHINA-HOSPEQ 2013 (booth #G02). On display in the booth will be system models and demonstration stations featuring various products and clinical illustrations. PLA General Hospital and Peking Union Medical College Hospital in Beijing are leading the charge with these new technologies, having already acquired the CyberKnife and TomoTherapy Systems. PLA General Hospital is the first and only China hospital with both systems. Cancer is one of the leading causes of mortality in China, with almost two million cancer deaths nationwide during 2008. The CyberKnife and TomoTherapy Systems give physicians in China the most innovative and precise treatment solutions to help make the pain and suffering of cancer a thing of the past, and provide new hope to more cancer patients.
"We are committed to strengthening our partnerships in China, with the government and distributors, to offer more patients the opportunity to benefit from our effective, personalized treatments," said Kelly Londy, executive vice president and chief commercial officer at Accuray.
"Our factory in Chengdu produces the TomoTherapy System's linear accelerators (linacs) for the global market. Accuray continues to invest in this factory with new machinery, and is continuing to further our commitment to quality, evidenced by the factory's ISO 9001 accreditation," said Roger Cao, M.D., Asia Pacific president at Accuray.
The TomoTherapy System is the only radiation therapy system designed specifically for image-guided, intensity-modulated radiation therapy. Its on-board CT scanner enables daily pre-treatment imaging for increased accuracy and the system's linear accelerator (linac) enables the continuous helical delivery of radiation from 360 degrees around the patient, providing for increased treatment precision.
"Clinicians use daily CT imaging to guide treatment based on the size, shape and location of tumors on the day of treatment, rather than treating based on how the tumors looked a week or a month ago. This ensures radiation delivery with the TomoTherapy System provides highly precise treatments," Dr. Cao said.
Accuray's CyberKnife System is the most innovative radiation oncology solution for treating and tracking moving targets with extreme precision and accuracy. It is the world's first and only robotic radiosurgery system, capable of delivering high-dose radiation therapy with sub-millimeter accuracy to any tumor, even those considered inoperable. It safely treats tumors anywhere in the body, including the lung and liver, two of the most prevalent cancers in China, and has been used to treat hundreds of thousands of patients worldwide. Treatment with the CyberKnife System is completely non-invasive and painless. It requires no anesthesia, involves no incision or overnight hospital stays, has minimal side effects, and allows patients to immediately resume their usual activities.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012, February 6, 2013, & May 9, 2013 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated